Users Discontinuing Weight-Loss Injections Regain Pounds at a Quadrupled Rate Compared to People Using Diet and Exercise

New research suggests that patients who discontinue new GLP-1 drugs like Wegovy and Mounjaro may regain lost weight much more quickly than those who end conventional diet and exercise regimens.

Findings released in a leading medical journal shows that while overweight individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.

"People using such drugs need to be cognizant of the potential of quick weight regain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.

That rate of regain means a reversion to pre-treatment weight within about one and a half years.

Weighing Therapies

The research, which looked at dozens of studies involving thousands of participants, contrasted the effects of the injectable medications with other pills.

Scientists emphasize that people who lose weight through lifestyle changes alone generally see a more gradual creep back—around 0.1 kg a month—after stopping.

The Reason for the Fast Rebound

Doctors propose the mode of action of the jabs is key to understanding the heightened weight return.

GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls appetite.

"Sustained high doses of GLP-1 levels several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.

"Withdrawal of this GLP-1 'fix' means appetite is no longer kept in check, making overeating much more probable."

A Lifelong Disease?

Medical guidelines suggest the jabs for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.

A number of clinicians argue that, due to the significant potential of weight regain, the therapy might need to be ongoing.

This opinion is reinforced by drug manufacturers, who say that the findings "emphasize the persistent character of excess weight," akin to managing diseases like diabetes.

User Experiences

Individuals who have stopped the medication describe a powerful resurgence of cravings.

"It felt as if a trigger that goes on and I was suddenly ravenous," recalled one woman.

This challenge is worsened if users have not established permanent dietary or behavioural changes during therapy.

Widespread Interest

Figures suggest that millions of adults in the UK have used these injections in the past year, with demand remaining high.

• Adoption is greater among women compared to males.
• The middle-aged demographic shows the greatest level of interest.
• A large proportion access the medications through private healthcare rather than the NHS.

Ultimately, clinicians emphasize that while these medications are powerful tools for shedding pounds, they are not a magic fix and long-term success likely depends on integrated lifestyle management.